Tag: disease modifying therapy

Guidance on Additional COVID-19 Vaccine Dose for MS Patients

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Patients age 12 years and older with multiple sclerosis (MS) who...

Rituximab Benefits Seen in Neuropsychiatric Lupus

Patients with neuropsychiatric manifestations of systemic lupus erythematosus (NPSLE) seem to benefit from rituximab (Rituxan) therapy, according to data from the British Isles Lupus Assessment...

Some MS Treatments May Heighten COVID Risk

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. When it comes to SARS-CoV-2 infection among patients with multiple sclerosis...

Evobrutinib May Help Reduce MS Nerve Damage

Oral evobrutinib, an investigational highly selective Bruton’s tyrosine kinase inhibitor, may have a beneficial effect on reducing nerve damage in multiple sclerosis¬†(MS), based on how...

Certain DMTs in MS May Attenuate COVID-19 Vaccines

Dr Amit Bar-Or COVID-19 vaccines are considered safe for patients with multiple sclerosis (MS), a neurologist told colleagues, but those who are on disease-modifying therapy...

COVID-19 Risks No Higher in Patients With Multiple Sclerosis

The risk of severe outcomes from COVID-19 infection in patients with multiple sclerosis seems to align with that seen in the general population, new US...

Serum NfL May Flag Subclinical Disease in Pregnant MS Patients

Among women with multiple sclerosis (MS), levels of serum neurofilament light (sNfL) are higher during pregnancy and the postpartum period. The increase in sNfL is...

Lessons for Patients With MS and COVID-19

Two important lessons about managing patients with multiple sclerosis (MS) and COVID-19 have emerged from a hospital clinic in Madrid that managed COVID-infected patients with...

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring serum levels of neurofilament light chain (NfL) is an effective way of detecting disease activity and the need to optimize treatment in patients with...

MS Disability, Not Drug Therapy, Tied to Worse COVID-19 Outcomes

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. In patients with MS, disability, age, and obesity were the main...

Ofatumumab Shows High Elimination of Disease Activity in MS

With ofatumumab (Arzerra, Novartis), a fully human anti-CD20 monoclonal antibody, there is a greater likelihood of there being no evidence of disease activity (NEDA-3) for...

Cautionary Findings on Immunodeficiency From Anti-CD20 MS Therapy

REPORTING FROM AAN 2020 Thirty-eight percent of a large cohort of multiple sclerosis (MS) patients developed low IgM and 7.4% became hypogammaglobulinemic during a mean...

Initial High-Efficacy MS Therapy Tied to Less Disability Later

Starting treatment for relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with lower long-term disability compared with a step-wise increase to reach more...